You are on page 1of 6

REFERENSI 1. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive dis-orders.

Prog Retin Eye Res 2005;24:493-519. 2. Mitchell P, Smith W, Chang A. Preva-lence and associations of retinal vein oc-clusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243-7. 3. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein oc-clusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-41. 4. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlu-sion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117(2):313.e1-319.e1 5. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthal-mol 2006;124:726-32. 6. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein oc-clusion: an evidence-based systematic re-view. Ophthalmology 2010;117(6):1113.e15-1123.e15. 7. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlu-sion: a population-based study. Am J Oph-thalmol 2005;139:181-2. 8. Greiner K, Hafner G, Dick B, Peetz D, Prellwitz W, Pfeiffer N. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69-74. 9. Incorvaia C, Lamberti G, Parmeggiani F, et al. Idiopathic central retinal vein oc-clusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin ge-notype. Am J Ophthalmol 1999;128:247-8. 10.Lahey JM, Tun M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002;109:126-31. 11.Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of

atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005;93:1021-6. 12.Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 1992;99:509-14. 13.Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases asso-ciated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77. 14.Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthal-mology 1990;97:1543-8. 15. Wong TY, Larsen EK, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthal-mology 2005;112:540-7. 16.Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the Multi-ethnic Study of Atherosclerosis. Invest Ophthalmol Vis Sci 2008;49:4297-302. 17.The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82. 18.Idem.Argon laser scatter photocoag-ulation for prevention of neovasculariza-tion and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986;104:34-41. 19.The Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-95. 20.Idem. A randomized clinical trial of early panretinal photocoagulation for is-chemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434-44. 21.Idem.Natural history and clinical man-agement of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-91. [Erra-tum, Arch Ophthalmol 1997;115:1275.]

22.Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein oc-clusion: an evidence-based systematic re-view. Ophthalmology 2010;117(6):1094.e5-1101.e5. 23.Finkelstein D. Ischemic macular ede-ma: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992;110:1427-34. 24.The Central Vein Occlusion Study Group. Evaluation of grid pattern photo-coagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-33. 25.Tsaloumas MD, Kirwan J, Vinall H, et al. Nine year follow-up study of mor-bidity and mortality in retinal vein occlu-sion. Eye (Lond) 2000;14:821-7. 26.Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M. Mortality in patients with branch retinal vein occlusion. Oph-thalmology 2007;114:1186-9. 27.Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mor-tality: pooled data analysis of 2 popula-tion-based cohorts. Ophthalmology 2007;114:520-4. 28.Hayreh SS, Rojas P, Podhajsky P, Mon-tague P, Woolson RF. Ocular neovascular-ization with retinal vascular occlusion. III. Incidence of ocular neovasculariza-tion with retinal vein occlusion. Ophthal-mology 1983;90:488-506. 29.Wong TY, Mitchell P. Hypertensive reti-nopathy. N Engl J Med 2004;351:2310-7. 30.McIntosh RL, Mohamed Q, Saw SMWong TY. Interventions for branch retinal vein occlusion: an evidence-based system-atic review. Ophthalmology 2007;114:835-54. 31.Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based system-atic review. Ophthalmology 2007;114:507-19.

32.Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ. Low molecular weight heparin for the treatment of retinal vein occlu-sion: a systematic review and meta-analy-sis of randomized trials. Haematologica 2010;95:158793. 33.Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal tri-amcinolone acetonide. Eye (Lond) 2005;19:65-71. 34.Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triam-cinolone with standard care to treat vi-sion loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study re-port 6. Arch Ophthalmol 2009;127:1115-28. [Erratum, Arch Ophthalmol 2009;127:1655.] 35.Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to reti-nal vein occlusion. Ophthalmology 2010;117(6):1134.e3-1146.e3. 36.Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degen-eration. N Engl J Med 2006;355:1432-44. 37. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. 38.Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in oc-ular fluid of patients with diabetic reti-nopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. 39.Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-9. 40.Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ra-nibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.

41.Wu L, Arevalo J, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central reti-nal vein occlusion: results of the Pan Amer-ican Collaborative Retina Study Group at 24 months. Retina 2010;30:1002-11. 42.Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12month results of a pro-spective clinical trial. Br J Ophthalmol 2009;93:452-6. 43.Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117(6):1102.e11112.e1. 44.McAllister IL, Gillies ME, Smithies LA, et al. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioreti-nal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010;117:954-65. 45.Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triam-cinolone with observation to treat vision loss associated with macular edema sec-ondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study re-port 5. Arch Ophthalmol 2009;127:1101-14. [Erratum, Arch Ophthalmol 2009;127:1648.] 46.Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central reti-nal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010;150:3104. 47.Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117(6):1124.e11133.e1. 48.Rouhani B, Mandava N, Olson JL. Central retinal vein occlusion after intense exercise in healthy patients. Retinal Cases Brief Rep 2010;4:105-8. 49.Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular de-generation. N Engl J Med 2007;356:748-9.

50.Wong TY. Age-related macular degen-eration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:327-9. 51.Retinal vein occlusion (RVO) interim guidelines. London: The Royal College of Ophthalmologists, February 2009. (http://www.rcophth.ac.uk.)

You might also like